-
1.发明申请VECTOR ENCODING THERAPEUTIC POLYPEPTIDE AND SAFETY ELEMENTS TO CLEAR TRANSDUCED CELLS 审中-公开编码治疗性多肽的载体和清除转导细胞的安全性元素公开(公告)号：US20100233200A1
公开(公告)日：2010-09-16
申请号：US12532572
申请日：2008-03-27
Applicant: Jeffrey A. Medin
Inventor： Jeffrey A. Medin
IPC: A61K39/385 , C12N15/74 , A61K31/7088 , C12N5/071 , A61K35/12 , A61P37/06
CPC classification number: A61K48/005 , A61K47/6825 , A61K47/6849 , A61K48/0083 , A61K2039/505 , C07K16/2866 , C07K2319/55 , C07K2319/74 , C12N9/1211 , C12N15/86 , C12N2740/15033 , C12N2740/15043 , C12N2740/17033 , C12N2740/17043 , C12N2750/14133 , C12N2750/14143 , C12N2799/027
Abstract: A composition comprising: a stably integrating delivery vector; an modified mammalian thymidylate kinase (tmpk) activator polynucleotide wherein the modified mammalian tmpk polynucleotide encodings a modified mammalian tmpk polypeptide that increases phosphorylation of converts a prodrug relative to phosphorylation of the prodrug by wild-type mammalian tmpk polypeptide to a drug; and/or a targeting polynucleotide encoding a cell surface polypeptide that selectively binds a toxic binding agent. The disclosure also relates to use of these compositions in methods of treatment of diseases such as Fabry disease.
Abstract translation: 一种组合物，其包含：稳定整合递送载体; 修饰的哺乳动物胸苷酸激酶（tmpk）激活剂多核苷酸，其中修饰的哺乳动物tmpk多核苷酸编码修饰的哺乳动物tmpk多肽，其增加将前体药物相对于通过野生型哺乳动物tmpk多肽磷酸化的药物转化为药物的磷酸化; 和/或编码选择性结合有毒结合剂的细胞表面多肽的靶向多核苷酸。 本公开还涉及这些组合物在治疗诸如法布里病的疾病的方法中的用途。
-
公开(公告)号：US20090068158A1
公开(公告)日：2009-03-12
申请号：US12052565
申请日：2008-03-20
Applicant: Jeffrey A. Medin , Arnon Lavie , Daniel H. Fowler , Boro Dropulic
Inventor： Jeffrey A. Medin , Arnon Lavie , Daniel H. Fowler , Boro Dropulic
IPC: A61K35/12 , A61K31/7088 , C12N15/87 , C12N5/10 , C12N15/63
CPC classification number: A61K48/005 , A61K38/00 , C12N9/1229 , C12N15/86 , C12N2740/16043 , C12Y207/04009 , Y02A50/473
Abstract: The invention relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods of treatment of diseaseuuius such as graft versus host disease and cancer.
Abstract translation: 本发明涉及一种组合物，其包含：稳定整合递送载体; 修饰的哺乳动物胸苷酸激酶（tmpk），其中修饰的哺乳动物tmpk增加了前体药物相对于通过野生型人类tmpk磷酸化前药的磷酸化。 本发明还涉及这些组合物在治疗疾病如移植物抗宿主病和癌症的方法中的用途。
-
公开(公告)号：US08765462B2
公开(公告)日：2014-07-01
申请号：US12598899
申请日：2008-05-05
Applicant: Jeffrey A. Medin , Christopher J. Paige
Inventor： Jeffrey A. Medin , Christopher J. Paige
CPC classification number: A61K35/545 , A61K38/208 , A61K39/0011 , A61K48/005 , A61K2039/515 , A61K2039/53 , A61K2039/585 , C07K14/5434 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/16122 , C12N2730/10122 , C12N2740/13043 , C12N2740/15043 , C12N2740/15071 , C12N2740/16022 , C12N2800/40 , C12N2830/48 , C12N2830/60
Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
Abstract translation: 公开了用于递送免疫调节分子以产生治疗效果的组合物和方法。 组合物和方法使用稳定整合的慢病毒递送系统。 该方法可用于治疗和预防性治疗诸如白血病的癌症。
-
公开(公告)号：US20110027310A1
公开(公告)日：2011-02-03
申请号：US12598874
申请日：2008-05-05
Applicant: Jeffrey A. Medin , Andrea McCart , Severine Loisel-Meyer
Inventor： Jeffrey A. Medin , Andrea McCart , Severine Loisel-Meyer
CPC classification number: A61K39/0011 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2227/105 , A01K2267/0331 , A61K38/208 , A61K39/21 , A61K48/005 , A61K2039/5154 , A61K2039/5156 , A61K2039/5256 , A61K2039/53 , A61K2039/55522 , A61K2039/55538 , A61K2039/57 , A61K2039/575 , C07K14/5434 , C07K14/70503 , C07K2319/06 , C12N7/00 , C12N15/8509 , C12N15/86 , C12N2740/15021 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , C12N2740/16043
Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer and prostate cancer.
Abstract translation: 公开了用于递送免疫调节分子以产生治疗效果的组合物和方法。 组合物和方法使用稳定整合的慢病毒递送系统。 该方法可用于治疗和预防性治疗癌症如结肠癌和前列腺癌。
-
公开(公告)号：US20100291043A1
公开(公告)日：2010-11-18
申请号：US12598899
申请日：2008-05-05
Applicant: Jeffrey A. Medin , Christopher J. Paige
Inventor： Jeffrey A. Medin , Christopher J. Paige
IPC: A61K35/12 , C12N15/867 , C12N7/01 , A61K31/7088 , C12N5/10 , C12P21/02 , A61P35/02 , A61P35/00 , A61P37/04
CPC classification number: A61K35/545 , A61K38/208 , A61K39/0011 , A61K48/005 , A61K2039/515 , A61K2039/53 , A61K2039/585 , C07K14/5434 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/16122 , C12N2730/10122 , C12N2740/13043 , C12N2740/15043 , C12N2740/15071 , C12N2740/16022 , C12N2800/40 , C12N2830/48 , C12N2830/60
Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
Abstract translation: 公开了用于递送免疫调节分子以产生治疗效果的组合物和方法。 组合物和方法使用稳定整合的慢病毒递送系统。 该方法可用于治疗和预防性治疗诸如白血病的癌症。
-
Patent Agency Ranking
公开(公告)号：US20100286046A1
公开(公告)日：2010-11-11
申请号：US12664824
申请日：2007-04-11
Applicant: Jeffrey A Medin , Joshua Daniel Silvertown , Alastair J.S. Summerlee
Inventor： Jeffrey A Medin , Joshua Daniel Silvertown , Alastair J.S. Summerlee
CPC classification number: C12N15/86 , A61K38/00 , A61K48/00 , C07K14/64 , C12N2740/10043
Abstract: Modified H2 relaxms which act as antagonists of the relaxm receptor in cells and tissues, in particular, modified H2 relaxms comprising one or more alterations of the ammo acid sequence at positions B 13, B17 and B20 located in the receptor binding domain The antagonists retain affinity to the receptor, but do not substantially activate the receptor once bound thereto The H2 relaxm antagonists are used in compositions and methods for the treatment of cancers wherein a relaxm receptor is expressed
Abstract translation: 充当细胞和组织中松弛受体的拮抗剂的修饰的H2松弛物，特别是包含位于受体结合结构域中位置B13，B17和B20处的氨基酸序列的一个或多个改变的修饰的H2松弛素。拮抗剂保持亲和力 但不能基本上活化一旦结合到其上的受体.H 2松弛素拮抗剂用于治疗癌症的组合物和方法，其中松弛受体被表达
-
公开(公告)号：US08445635B2
公开(公告)日：2013-05-21
申请号：US12664824
申请日：2007-04-11
Applicant: Jeffrey A Medin , Joshua Daniel Silvertown , Alastair J. S. Summerlee
Inventor： Jeffrey A Medin , Joshua Daniel Silvertown , Alastair J. S. Summerlee
IPC: C07K14/00
CPC classification number: C12N15/86 , A61K38/00 , A61K48/00 , C07K14/64 , C12N2740/10043
Abstract: Modified H2 relaxms which act as antagonists of the relaxm receptor in cells and tissues, in particular, modified H2 relaxms comprising one or more alterations of the ammo acid sequence at positions B 13, B17 and B20 located in the receptor binding domain The antagonists retain affinity to the receptor, but do not substantially activate the receptor once bound thereto The H2 relaxm antagonists are used in compositions and methods for the treatment of cancers wherein a relaxm receptor is expressed.
Abstract translation: 充当细胞和组织中松弛受体的拮抗剂的修饰的H2松弛物，特别是包含位于受体结合结构域中位置B13，B17和B20处的氨基酸序列的一个或多个改变的修饰的H2松弛素。拮抗剂保持亲和力 但不能基本上活化一旦结合到其上的受体.H 2松弛素拮抗剂用于治疗其中表达松弛素受体的癌症的组合物和方法中。
-
公开(公告)号：US20110104130A1
公开(公告)日：2011-05-05
申请号：US12933460
申请日：2009-03-20
Applicant: Jeffrey A. Medin , Sean Devine
Inventor： Jeffrey A. Medin , Sean Devine
IPC: A61K35/12 , C12N15/63 , C12N15/85 , C12N5/00 , C12N9/12 , C12N15/54 , A61K31/7052 , C12N7/00 , A61K35/76 , A61P35/00 , A61P3/00
CPC classification number: A61K48/0058 , A61K38/00 , C07H21/04 , C07K14/70503 , C07K2319/00 , C12N5/16 , C12N9/1229 , C12N15/63 , C12N15/85 , C12N15/86 , C12N15/861 , C12N15/8645 , C12N15/867 , C12N2740/15041 , C12N2740/15043 , C12N2740/16043 , C12N2840/203 , C12Y207/04009
Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.
Abstract translation: 本申请涉及一种组合物，其包含：稳定整合递送载体; 修饰的哺乳动物胸苷酸激酶（tmpk），其中修饰的哺乳动物tmpk增加了前体药物相对于野生型人类tmpk前药的磷酸化的磷酸化; 和与tmpk融合的检测盒。 本申请还涉及这些组合物在治疗疾病如移植物抗宿主病和癌症的方法中的用途。
-
公开(公告)号：US08568709B2
公开(公告)日：2013-10-29
申请号：US12933460
申请日：2009-03-20
Applicant: Jeffrey A. Medin , Sean Devine
Inventor： Jeffrey A. Medin , Sean Devine
CPC classification number: A61K48/0058 , A61K38/00 , C07H21/04 , C07K14/70503 , C07K2319/00 , C12N5/16 , C12N9/1229 , C12N15/63 , C12N15/85 , C12N15/86 , C12N15/861 , C12N15/8645 , C12N15/867 , C12N2740/15041 , C12N2740/15043 , C12N2740/16043 , C12N2840/203 , C12Y207/04009
Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.
Abstract translation: 本申请涉及一种组合物，其包含：稳定整合递送载体; 修饰的哺乳动物胸苷酸激酶（tmpk），其中修饰的哺乳动物tmpk增加了前体药物相对于野生型人类tmpk前药的磷酸化的磷酸化; 和与tmpk融合的检测盒。 本申请还涉及这些组合物在治疗疾病如移植物抗宿主病和癌症的方法中的用途。
-
公开(公告)号：US20110014165A1
公开(公告)日：2011-01-20
申请号：US12843238
申请日：2010-07-26
Applicant: Jeffrey A. Medin , Arnon Lavie , Daniel H. Fowler
Inventor： Jeffrey A. Medin , Arnon Lavie , Daniel H. Fowler
CPC classification number: A61K38/45 , A01K2267/0331 , C12N9/1229 , C12N2799/027 , C12N2840/203 , C12Y207/04009 , Y02A50/473
Abstract: The invention relates to a composition comprising a stably integrating delivery vector; and a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.
Abstract translation: 本发明涉及包含稳定整合递送载体的组合物; 和修饰的哺乳动物胸苷酸激酶（tmpk），其中修饰的哺乳动物tmpk增加了前体药物相对于通过野生型人类tmpk磷酸化前药的磷酸化。 本发明还涉及这些组合物在治疗疾病如移植物抗宿主病和癌症的方法中的用途。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.024 seconds)
